MEDIFAST, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.71 USD | +0.63% |
|
+3.91% | -49.85% |
| Feb. 20 | Medifast, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 20 | Transcript : Medifast, Inc., Q4 2023 Earnings Call, Feb 20, 2024 |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The company shows low valuation levels, with an enterprise value at 0.26 times its sales.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -49.85% | 365M | C- | ||
| +8.20% | 7.78B | D+ | ||
| +1.64% | 7.38B | C- | ||
| +10.20% | 6.52B | - | ||
| -8.10% | 3.67B | D | ||
| -14.57% | 1.17B | - | - | |
| +8.34% | 934M | - | ||
| -42.27% | 879M | B+ | ||
| -18.90% | 836M | C+ | ||
| -16.45% | 802M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MED Stock
- Ratings Medifast, Inc.
